Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic

  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CinCor Pharma, Inc. - Common Stock (NQ: CINC )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CinCor Pharma, Inc. - Common Stock

< Previous 1 2 3 4 Next >
CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat
From CinCor Pharma Inc
Via GlobeNewswire
There's a Lot to Love About Mineralys' Valentine's Day IPO
MLYS added 20% more shares to IPO funding, which goes live on 2/14. The bump secured liquidity to stabilize development, improving market cap to $683 million 
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
These 2 Healthcare Stocks Have Doubled in 2023
Wouldn’t it be great if a stock had a bulkier capitalization and 2x potential? This is rare but possible for these two small-mid health care stocks. 
Via MarketBeat
CINCOR PHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CinCor Pharma, Inc. - CINC
From Kahn Swick & Foti, LLC
Via Business Wire
Where CinCor Pharma Stands With Analysts
Via Benzinga
Where CinCor Pharma Stands With Analysts
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Paya Holdings Inc. (Nasdaq – PAYA), CinCor Pharma, Inc. (Nasdaq – CINC), Albireo (Nasdaq – ALBO), Duck Creek Technologies (Nasdaq - DCT)
From Brodsky & Smith LLC
Via GlobeNewswire
Why These Two Biotech Stocks Blasted Higher This Week
There's nothing like a big-premium buyout to send a company's share price to the moon. 
Via The Motley Fool
Stock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review
Sharp Tesla price cuts and some notable earnings were in focus. 
Via Investor's Business Daily
CINCOR PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CinCor Pharma, Inc. - CINC
From Kahn Swick & Foti, LLC
Via Business Wire
AstraZeneca Stock Nabs Breakout After $1.8 Billion CinCor Buyout
CinCor will bolster AstraZeneca's growing cardio-renal business. 
Via Investor's Business Daily
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Paya Holdings Inc. (Nasdaq – PAYA), CinCor Pharma, Inc. (Nasdaq – CINC), Albireo (Nasdaq – ALBO), Duck Creek Technologies (Nasdaq - DCT)
From Brodsky & Smith LLC
Via GlobeNewswire
S&P 500 Gains 0.6%; Albireo Pharma Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Monday. 
Via Benzinga
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Stocks Building Off Of Friday's Rally
The Dow Jones Industrial Average is up more than 280 points midday, while the Nasdaq Composite Index is also up triple digits. 
Via Talk Markets
Nasdaq Surges Over 200 Points; Crude Oil Rises 2%
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Monday. 
Via Benzinga
CinCor Pharma (NASDAQ: CINC) Enters Into Agreement to be Acquired by AstraZeneca (NASDAQ: AZN) for $1.3 Billion
CinCor Pharma, Inc. (NASDAQ: CINC) is a clinical-stage biopharmaceutical company, which is focused on the research and development of treatments 
Via Spotlight Growth
AstraZeneca To Acquire Blood-Pressure Drugmaker In $1.8 Billion Deal
AstraZeneca stock wavered as it agreed to buy CinCor Pharma, maker of blood pressure drug baxdrostat for $1.8 billion. CINC stock soared. 
Via Investor's Business Daily
Why Is CinCor (CINC) Stock Up 138% Today?
CinCor (CINC) stock is rocketing higher on Monday following news that AstraZeneca (AZN) is acquiring the company for up to $1.8 billion. 
Via InvestorPlace
Tesla, Zillow, Albireo Pharma And Some Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Dow Jones gaining more than 150 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
US Stocks Open Higher; Dow Rises 150 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining around 150 points on Monday. 
Via Benzinga
CINC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CinCor Pharma, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Tesla's Delivery Wait Times Go Up, China Wants To Secure License For Generic Version Of Pfizer's Paxlovid, India-Made iPhone Exports Surpass $2.5B: Today's Top Stories
Bloomberg 
Via Benzinga
AstraZeneca To Acquire CinCor Pharma To Strengthen Cardiorenal Pipeline
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why CinCor Pharma Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) rose 140.2% to $28.30 in pre-market trading after AstraZeneca announced plans to buy the company for up to $1.8 billion. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning! 
Via InvestorPlace
CinCor Pharma to be Acquired by AstraZeneca
From CinCor Pharma Inc
Via GlobeNewswire
Analyzing CinCor Pharma's Short Interest
CinCor Pharma's (NASDAQ:CINC) short percent of float has risen 4.28% since its last report. The company recently reported that it has 2.25 million shares sold short, which is 8.78% of all regular... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.